Host-Pathogen Relationships among Escherichia coli Isolates Recovered from Men with Febrile Urinary Tract Infection
Open Access
- 15 March 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (6) , 813-822
- https://doi.org/10.1086/428048
Abstract
Background. Host-pathogen relationships in men with febrile urinary tract infection (FUTI) are poorly understood. Methods. Phylogenetic background, extended virulence genotypes, and serotypes were determined for 70 Escherichia coli isolates recovered from urine samples obtained from men with FUTI for comparison with available data for 70 E. coli rectal isolates recovered from uninfected men. Bacterial traits were assessed in relation to underlying host characteristics (age, compromise status, and history of urinary tract infection) and acute manifestations (bacteremia, flank pain, and serum prostate-specific antigen [PSA] level). Results. Compared with rectal isolates, FUTI isolates exhibited a significantly higher prevalence of virulence-associated phylogenetic groups, serotypes, and extraintestinal virulence genes. The latter included traditional prostatitis-associated traits (e.g., hemolysin and cytotoxic necrotizing factor), as well as unconventional traits, such as outer membrane protease T. These bacterial traits occurred largely independent of host age, urological compromise status, urinary tract infection history, and acute manifestations. However, certain traits were less prevalent in association with use of urinary tract instrumentation and significantly predicted elevated PSA levels. Conclusions. Considerable virulence capability may be required for an E. coli strain to cause FUTI in men, regardless of whether most compromising conditions are present. Bacterial traits that promote prostatic invasion may be relevant for the pathogenesis of FUTI, even among men without classic manifestations of acute prostatitis.Keywords
This publication has 32 references indexed in Scilit:
- Legionnaires' disease: a rational approach to therapyJournal of Antimicrobial Chemotherapy, 2003
- Legionella pneumophila Pneumonia Successfully Treated with Intravenous Ciprofloxacin.Internal Medicine, 2002
- In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumoniaJournal of Antimicrobial Chemotherapy, 1996
- Antimicrobial Chemotherapy for Legionnaires' Disease: A ReviewClinical Infectious Diseases, 1995
- Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophilaAntimicrobial Agents and Chemotherapy, 1995
- Rote of the quinolones in the treatment of legionellosisJournal of Antimicrobial Chemotherapy, 1991
- Comparison of the activity of three antibiotic regimens in severe Legionnaires' diseaseJournal of Antimicrobial Chemotherapy, 1990
- Brief report: Ciprofloxacin in the treatment of legionellosis in critically III patients including those cases unresponsive to erythromycinThe American Journal of Medicine, 1989
- Ciprofloxacin: a preferred treatment for legionella infections in patients receiving cyclosporin AJournal of Antimicrobial Chemotherapy, 1988
- Legionnaires' DiseaseNew England Journal of Medicine, 1977